NCT07419698

Evaluate the Safety, Tolerability, PK, and PD of JMT206 Injection in Healthy Participants

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMT206 Injection in Healthy Subjects

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 44 (estimated)
• Sponsor: Shanghai JMT-Bio Inc. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

A This is a single-center, randomized, double-blind, placebo-controlled, dose-escalation Phase I clinical trial. It aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single administration of JMT206 Injection in healthy participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
BIOLOGICAL	JMT206	Subcutaneous injection, single dose.
DRUG	Placebo	Subcutaneous injection, single dose.

Timeline

• Start date: 2026-01-26
• Primary completion: 2026-09-01
• Completion: 2026-11-01
• First posted: 2026-02-19
• Last updated: 2026-02-19

Locations

1 site across 1 country: China